Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
Top tierWe are a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Our current portfolio is comprised of highly differentiated topical and systemic treatments with significant potential to treat immune-mediated dermatological diseases and conditions. We believe we have built a leading platform for dermatologic product development and commercialization.
In the company’s own words · 10-K filed Feb 25, 2026 · SEC EDGAR
Business segments
Q1 2026 · $105.4MThe company’s own SEC segment disclosure.
- ZORYVE Foam$49.6M47%
- ZORYVE Cream0.3$32.7M31%
- ZORYVE Cream0.15$21.7M21%
- ZORYVE Cream0.05$1.4M1%
Arcutis Biotherapeutics, Inc. (ARQT) reported revenue of $130M in Q2 2026 (quarter ended June 30, 2026), up 59% from the same quarter a year earlier. That came with a gross margin of 92% and net income of $15M (12% of revenue). For the full year FY2025, revenue was $376M (+91% year on year) and net income −$16M. Its largest product in 2026-Q1 was ZORYVE Foam at $50M, 47% of the disclosed total, just ahead of ZORYVE Cream0.3 at 31%.
Raw charts
10 series · TTMAs reported to the SEC, without any scoring.